RIVANOVA
Insights
Long-form thinking on formulation science, quality systems, regulatory change and the economics of access.
Insights
Long-form pieces on formulation science, quality systems, regulatory change and the economics of access — written by the people doing the work, not by an agency.
Showing all 6 items
A dissolution profile that passes in purified water can still under-deliver in a fed stomach. What biorelevant media revealed about three of our own formulations.
Most citations are not fraud — they are systems that made the compliant path slower than the shortcut. Six technical controls that remove the choice entirely.
The five modules where emerging-market submissions most often stall, and how to build Module 3 so the reviewer never needs to ask for the same thing twice.
A paediatric suspension a child refuses is a treatment that did not happen. What we learned from reformulating a bitter macrolide three times.
Affordability gets the headlines. In three of our export markets, product loss to temperature excursion cost more than the entire price differential.
Phase I laboratory investigation is where most OOS enquiries go wrong. A working method for separating analytical error from a genuine manufacturing signal.
Subscribe below and you will receive each piece in full, along with regulatory updates and manufacturing milestones — four emails a year, no more.